{"id":"eraxis-anidulafungin","safety":{"commonSideEffects":[{"rate":null,"effect":"Elevated liver enzymes (ALT/AST)"},{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Anidulafungin is an echinocandin antifungal that selectively inhibits 1,3-beta-D-glucan synthase, a key enzyme in fungal cell wall biosynthesis. By preventing glucan polymerization, it disrupts the structural integrity of the fungal cell wall, causing cell lysis and death. This mechanism is fungicidal against Candida species and has activity against Aspergillus.","oneSentence":"Anidulafungin inhibits fungal cell wall synthesis by blocking the enzyme glucan synthase, leading to fungal cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:29:32.654Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Candidemia and other Candida infections (intra-abdominal candidiasis, peritonitis, esophageal candidiasis)"},{"name":"Aspergillus fumigatus infections"}]},"trialDetails":[{"nctId":"NCT05178862","phase":"PHASE3","title":"A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole","status":"TERMINATED","sponsor":"Scynexis, Inc.","startDate":"2022-08-03","conditions":"Candidiasis, Invasive, Candidemia","enrollment":68},{"nctId":"NCT05426499","phase":"","title":"Translational PKPD Modeling of Anti-infective Drugs Used in Pediatric Units.","status":"RECRUITING","sponsor":"Poznan University of Medical Sciences","startDate":"2021-10-01","conditions":"Population Modeling of Anti-infective Drugs","enrollment":150},{"nctId":"NCT06907992","phase":"","title":"A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated Candidemia","status":"NOT_YET_RECRUITING","sponsor":"Augusta University","startDate":"2025-05-01","conditions":"Candidemia","enrollment":150},{"nctId":"NCT01686607","phase":"","title":"Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2012-10-01","conditions":"Systemic Fungal Infections","enrollment":40110},{"nctId":"NCT04045366","phase":"","title":"Impact of Capillary Leak and Hypoalbuminemia on PK/PD of Anidulafungin and Caspofungin in Critically Ill Patients","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2012-09-21","conditions":"Critically Ill Patients","enrollment":60},{"nctId":"NCT04876716","phase":"PHASE3","title":"Azole-echinocandin Combination Therapy for Invasive Aspergillosis","status":"TERMINATED","sponsor":"Erasmus Medical Center","startDate":"2021-05-11","conditions":"Invasive Aspergillosis","enrollment":66},{"nctId":"NCT00934934","phase":"PHASE2","title":"Candida in the Respiratory Tract Secretions of Critically Ill Patients and The Efficacy of Antifungal Treatment","status":"TERMINATED","sponsor":"Daren K. Heyland","startDate":"2010-04","conditions":"Ventilator Associated Pneumonia, Respiratory Tract Infection","enrollment":61},{"nctId":"NCT01249820","phase":"PHASE2","title":"Pharmacokinetics of Anidulafungin (Ecalta ®) Intravenous Given to Patients at High Risk for Developing Invasive Fungal Disease","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2010-11","conditions":"Leukemia, Myelodysplastic Syndrome, Leukemia, Myeloid, Acute","enrollment":26},{"nctId":"NCT02021123","phase":"PHASE4","title":"Anidulafungin Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (ADOPT)","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2014-08","conditions":"Obesity Morbid","enrollment":8},{"nctId":"NCT01734525","phase":"PHASE4","title":"Negative Beta Glucan in ICU Patients","status":"COMPLETED","sponsor":"Universidade Federal do Rio de Janeiro","startDate":"2012-11","conditions":"Candidemia","enrollment":85},{"nctId":"NCT00761267","phase":"PHASE3","title":"Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-02","conditions":"Candidemia","enrollment":70},{"nctId":"NCT01307930","phase":"PHASE4","title":"Effect of Weight and/or Obesity on Anidulafungin Drug Concentrations","status":"COMPLETED","sponsor":"Texas Tech University Health Sciences Center","startDate":"2011-01","conditions":"Obesity, Mycoses","enrollment":20},{"nctId":"NCT00802854","phase":"","title":"Post Marketing Surveillance Study To Observe Safety And Efficacy Of Eraxis® IV","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-03-02","conditions":"Candidemia, Other Forms of Candida Infections(Intra-abdominal Abscess, Peritonitis)","enrollment":244},{"nctId":"NCT01213823","phase":"","title":"Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins","status":"TERMINATED","sponsor":"Pfizer","startDate":"2008-09","conditions":"Invasive Candidiasis, Candidemia","enrollment":536},{"nctId":"NCT01176058","phase":"PHASE3","title":"A Study Of The Efficacy And Safety Of Anidulafungin Vs. Fluconazole In The Treatment Of Patients With Candidemia And/Or Other Forms Of Invasive Candidiasis","status":"TERMINATED","sponsor":"Pfizer","startDate":"2010-12","conditions":"Candidemia","enrollment":17},{"nctId":"NCT00672841","phase":"NA","title":"β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients","status":"COMPLETED","sponsor":"Duke University","startDate":"2008-06","conditions":"Invasive Candidiasis","enrollment":64},{"nctId":"NCT00841971","phase":"PHASE4","title":"Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2010-02","conditions":"Mycoses, Fungemia, Central Nervous System Fungal Infections","enrollment":200},{"nctId":"NCT01303549","phase":"PHASE4","title":"Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2011-11","conditions":"Liver Disease, Fungal Infection","enrollment":61},{"nctId":"NCT01202253","phase":"","title":"Early Clinical Experience With Anidulafungin In Patients With Liver Disease In The United Kingdom","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-02","conditions":"Candidiasis","enrollment":50},{"nctId":"NCT00805740","phase":"PHASE3","title":"An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Deep Tissue Infection Due To Candida","status":"TERMINATED","sponsor":"Pfizer","startDate":"2009-04","conditions":"Candidiasis, Fungemia","enrollment":41},{"nctId":"NCT00068471","phase":"PHASE1, PHASE2","title":"Anidulafungin in Treating Immunocompromised Children With Neutropenia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-07","conditions":"Infection, Neutropenia, Unspecified Childhood Solid Tumor, Protocol Specific","enrollment":""},{"nctId":"NCT00806351","phase":"PHASE3","title":"An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System","status":"TERMINATED","sponsor":"Pfizer","startDate":"2009-08","conditions":"Fungemia, Neutropenia, Candidiasis","enrollment":21},{"nctId":"NCT00734500","phase":"PHASE1","title":"Anidulafungin PK in Infants and Toddlers","status":"COMPLETED","sponsor":"Michael Cohen-Wolkowiez","startDate":"2008-01","conditions":"Invasive Fungal Infections","enrollment":15},{"nctId":"NCT00491426","phase":"","title":"Antimicrobial PK in Infants With Suspected or Confirmed Infection","status":"COMPLETED","sponsor":"Duke University","startDate":"2006-01","conditions":"Infection","enrollment":450},{"nctId":"NCT01188759","phase":"PHASE3","title":"Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2012-05","conditions":"Aspergillosis, Invasive Pulmonary Aspergillosis, Neuroaspergillosis","enrollment":""},{"nctId":"NCT00531479","phase":"PHASE3","title":"Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-07","conditions":"Aspergillosis","enrollment":459},{"nctId":"NCT01047267","phase":"","title":"Pharmacokinetics of Anidulafungin on Intensive Care Unit (ICU)","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2010-06","conditions":"Invasive Candidiasis, Critically Ill","enrollment":20},{"nctId":"NCT01053884","phase":"PHASE2","title":"Anidulafungin in Patients With Hematologic Malignancies","status":"TERMINATED","sponsor":"Elisabethinen Hospital","startDate":"2009-10","conditions":"Hematologic Malignancies","enrollment":10},{"nctId":"NCT01270490","phase":"PHASE3","title":"Efficacy of Interferon-gamma in Combination With Anidulafungin for the Treatment of Candidemia","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2011-01","conditions":"Candidemia","enrollment":20},{"nctId":"NCT00496197","phase":"PHASE4","title":"Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-07","conditions":"Candidiasis","enrollment":282},{"nctId":"NCT01438216","phase":"","title":"Anidulafungin Pharmacokinetics in Intensive Care Unit Patients","status":"UNKNOWN","sponsor":"Amsterdam UMC, location VUmc","startDate":"2011-09","conditions":"Invasive Candidiasis, Candidemia","enrollment":20},{"nctId":"NCT00689338","phase":"PHASE3","title":"Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-07","conditions":"Invasive Candidiasis","enrollment":216},{"nctId":"NCT00548262","phase":"PHASE4","title":"This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-02","conditions":"Candidemia, Invasive Candidiasis","enrollment":54},{"nctId":"NCT00537329","phase":"PHASE3","title":"Anidulafungin In Treatment Of Candidemia In Asian Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-01","conditions":"Candidemia","enrollment":43},{"nctId":"NCT00620074","phase":"PHASE4","title":"Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)","status":"TERMINATED","sponsor":"Pfizer","startDate":"2008-08","conditions":"Aspergillosis","enrollment":6},{"nctId":"NCT00940017","phase":"PHASE4","title":"A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-09","conditions":"Aspergillosis, Candidemia","enrollment":24},{"nctId":"NCT00892359","phase":"PHASE2","title":"Anidulafungin During Continuous Venovenous Hemofiltration (CVVHF)","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2009-04","conditions":"Acute Renal Failure, Infection","enrollment":10},{"nctId":"NCT00056368","phase":"PHASE3","title":"The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-03","conditions":"Candidiasis","enrollment":256},{"nctId":"NCT00037206","phase":"PHASE2, PHASE3","title":"A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).","status":"COMPLETED","sponsor":"Pfizer","startDate":"2002-05","conditions":"Aspergillosis","enrollment":30},{"nctId":"NCT00037219","phase":"PHASE2","title":"The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2001-08","conditions":"Candidiasis","enrollment":120},{"nctId":"NCT00056381","phase":"PHASE1, PHASE2","title":"Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children Ages 2-17","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-07","conditions":"Neutropenia","enrollment":25},{"nctId":"NCT00041704","phase":"PHASE2","title":"The Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis (FRMC)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2002-08","conditions":"Candidiasis","enrollment":19},{"nctId":"NCT00058682","phase":"PHASE3","title":"Anidulafungin Versus Fluconazole in the Treatment of Candidemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-04","conditions":"Candida, Candidiasis","enrollment":248}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1300,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Eraxis (anidulafungin)","genericName":"Eraxis (anidulafungin)","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anidulafungin inhibits fungal cell wall synthesis by blocking the enzyme glucan synthase, leading to fungal cell death. Used for Candidemia and other Candida infections (intra-abdominal candidiasis, peritonitis, esophageal candidiasis), Aspergillus fumigatus infections.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}